Compounded tirzepatide
Sold by Tablet · Oral tablet · every compounded tirzepatide record
What you actually pay
Per month
$199
| Medication · Oral Tirzepatide, starting price | $199 |
|---|
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Oral Tirzepatide, starting price “Oral Tirzepatide Starting at $199/mo” | Per month$199 | Charged today$199 |
We earn nothing from this link. Tablet has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
One reading so far. A price history appears here after the next verification pass.
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Cancellation | “You may cancel your subscription at any time by emailing info@tablethealth.com or directly through your online account. Cancellation will take effect at the end of the current subscription period.” |
|---|
Not yet checked: pharmacy, states, prescriber, membership and consult fee.
Recorded from tablethealth.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2, 2026 — The homepage price grid visually mismatches its own sub-labels (e.g. the 'Oral Tirzepatide' card is tagged 'Injection' and the 'Compounded Tirzepatide' card is tagged 'Pill' in this tool's text output) — the individual product pages confirm the correct form (Compounded = weekly injection, Oral = daily pill), so form was taken from the product pages rather than the jumbled homepage tags, while price quotes were taken from the homepage card title + price line only (the mismatched tag text was excluded from the quotes to avoid misattributing form via a garbled quote). Tirzepatide oral product is recorded under the 'compounded tirzepatide' enum value since the brief's drug list has no distinct 'oral tirzepatide' option separate from 'oral semaglutide' being the only oral-specific enum entry — actually the enum does list 'oral semaglutide' but no 'oral tirzepatide'; there is no FDA-approved oral tirzepatide brand, and the site markets it as a compounded oral formulation, so 'compounded tirzepatide' + form 'oral-tablet' was used as the closest fit. FAQ has 'What states do you ship to?' as a question with no rendered answer (accordion). No sync/async prescriber description found; terms only mention needing a device 'with a video camera' as a general requirement, not confirmation that weight-loss visits are live video calls, so prescriber left not-found rather than guessed. A 'Quattro' product appears in the footer treatments list (name suggests a 4-drug combo) but was not investigated as it falls outside GLP-1-named entries and no dedicated page link was available.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.